HUE027448T2 - Szignál influenza vírusvektorok pakolására - Google Patents
Szignál influenza vírusvektorok pakolására Download PDFInfo
- Publication number
- HUE027448T2 HUE027448T2 HUE03716017A HUE03716017A HUE027448T2 HU E027448 T2 HUE027448 T2 HU E027448T2 HU E03716017 A HUE03716017 A HU E03716017A HU E03716017 A HUE03716017 A HU E03716017A HU E027448 T2 HUE027448 T2 HU E027448T2
- Authority
- HU
- Hungary
- Prior art keywords
- virus
- sequences
- nucleotides
- cells
- reading frame
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16241—Use of virus, viral particle or viral elements as a vector
- C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (8)
- Szignál influenza vírusvektorok pakolására SZABADALMI lÖÉSr^POMfOK 1. influenza vírus vektor rekondnnáns vRNS expresszálásához és pakolásához, amely x^ekíor a kóveíkezlkeí taÁaln^zza; az Influenza vírus nukleinsav vRNS 3’ nem- kódoló régiójának megfelelő .szekvenciák, és nuklelnsav kódoló szekvenciák, amelyek tartalmazzák a 3’ nukleinsav beépítési szekvenciákat, egy heterolég nukleinsav szegmens, amélv tartalmaz egy beíerolóe nyitott leolvasási keretet, nnklemsav kódoló szekvenciák,: amelyek tartalmazzák az 3* nnkieinsáv beépiési szekveneiákal, Is a nukleinsav vRNS 5’ nemákódoió régiót, áhöl a nbkleinsav kódoló szekvenciák, amely tartalmazzák a 35 thikleínsav beépítési szekvenciákat, legalább M nnkleotldot tartalmaznák egészen 230 nukleoíidíg, amelyek m i* nukleinsav kódoló oukleotfdjai 1-t 1-től 1-23041: terjedő nukleotidjait tartalmazzák, Is aböi az- S nnkleínsav beépítési szekvenellkat tartalmazó ftVikletrtsavAódoló szekvenelák legalább 39 niAJeotidot tartalmaznak ma-wmm 25Q nnkleotídig, amelyek a 3’ nnktelnsav-kődolő szekvenciák & 39 legszélső 3" eukleotidtól a 251 legszélső 3’ nukieotidig terjedő mMeotidokat. tartalmazzák, és ahol a vektor nem kádöl funkcionális nukleinsavat.
- 2. Az 1. igénypont szédAÉ vektor, amelyben a nukleinsavat kódoló szekvenciák, amelyek 3’ .nukleinsav beépítési szekvendákat tartalmaznak, mn&lrnaznak legalább 90 nukkotidot, amelyek megfeieinek a nukleinsavat kódoló 5’ 1-90. uukkmtidnak.
- 3.. Az L vagy 2. igénypont szerinti vektor, amelyben, a nukleinsavat kódoló szekvenciák, amelyek 3'' nukleinsav beépítési szekvenciákat tartalmaznak, tartalmaznak legalább 183 nukkmúdot, amelyek megfelelnek a nuMeitisavsí kódoló 3’ 1 -183. nukieotidnak.
- 4. Az I. vagy 2, igénypont szerinti vektor, amelyben a nukleinsavat kódoló szekvenciák, amelyek 3’ nukleinsav beépítési szekvendákat. tartalmaznak, maximum 183 nukleoddot tartalmaznak, amelyek megfelelnek a nukleinsavat kódoló 5' 1-183. nukieotidnak. és amelyben a nukté-iasavat kódoló szekvenciák, amdyék 5* nukleinsav beépítési jszekveoeiákaf tartalmaznak, maki-műm 157 nnkleotidot tartalmaznak, amelyek megfelelnek a nnklemsavai kódoló nukleotidok közül a 152 legszélső 3* nukleotidnak,
- 5, Az 1-4. tgénpontok bármelyike szerinti vektor, amelyben a heterolég nukleinsav szegmens tartalmaz még egy belső riboszömális belépési szekvenciát
- 6. Az 1-4. igénypontok bármelyike szerinti vektor, amelyben a heíerolog nyitott leolvasási keret olyan szekvenciákat mrialmaz, amelyek megfelelnek egy master gén nyitott leolvasási keretének, % ái 1-4. igénypontok; bármelyike szerinti vektor, amelyben a heieroíőg nyitott leolvasási keret olyan szekvenciákat tartalmaz, amelyek megfelelnek egy patogén: tnmrnnngén fehérjéjén nek vagy egypeptkifének, vagy ggy terápiás fehérjének, II, .á& 1-4. igénypontok bármelyike szerinti vektor, amelyben a beépítés! szekvenciák egy A típusú influenza vírusból származnak. 3, ,M·· 1-4. igénypontok bármelyike szerinti vektor, amelyben a beépiári szekvenciák egy B típusa influenza vírusból származnak. :!$> M11-4, igértypontok: bármelyike szerinti vektor, amelyben a beterolog nyitott leolvasási keret egy hlziős fehérjét kódol. 11. iekontbináns influenzavirus, amely m 1-4, igénypontok btetelyike szerinti vektornak megfelelő vRNS-t tartalmaz, 12. :A 11, igénypont szerinti fekombináns wl, amelyben a Iheternlőg nyitott leolvasási keret egy maZketgén nyitott leolvasási keretének megfelelő szekvenciákat tartalmaz.
- 13. A il, igénypont szerinti rekombináns Okos, amelyben aímterológ nyitóit leolvasási keret egy Ipátogén immunogen .fehérjéje- vagy egy peptfdje, vagy egy terápiás fehérje nyitott leolvasási keretének megfelelő szelmenel&.at tatíalmaz. 1.4. A 11. igénypont szerinti rekombináns vírus, amelyben a beterológ nyitott leolvasási keret egy HA fehérjét kódol. 15. A 11, fgéhyfmnt szerint! rekombináns vfes, amelyben a heteroiog nyitott leolvasási keret egy traBSzmembfán felérje nyitott; leolvasási keretén^ megfelelő szekvenciákat tartalmaz. 16. A 11. igénypont szerinti rekombináns vírus, amelyben a helerológ nyitott leolvasási keret egy uremfeáo-fezionÉtátó aktivitással feubelkező fehérje nyitott leolvasási keretének megfelelő szekvenciákat, tartalmaz. 17. A 11, igénypont szerinti rekombináns vfms, amelyben a leterolőg nyitott leolvasási keret egy virális kapziá febirje nyitott leolvasási keretének: megfelelő szekvenciákat tartalmaz, Íl.. A ll, igfetypnt szerimi mlmmbináns vírus, ámelpeo a letérőkig nyitott leolvasol keret egy hólyagos száj gyulladás vims G felérje nyitott leolvasási kemtének ntegfelelő szekvenciáké tartalmaz, 1:9. A 13, ipnypom szerími mfembináns vfms. amelyben a leterolőg nyitott leolvasást keret egy terápiás felélje nyitott leolvasást keretének megfelelő szekvenciákat tartalmaz. 2(1, A 14, Igfetyponi szerinti rekombmlns víms, amelyben a HA fehérje egy B típusú HA. fehérje, 21 lijáris egy nyitott leolvasási keret expressMilatására egy sejtben, .azzal jelMmezve, hpgy a kivetkező lépéseket lartakpam; egy sejtet in vitrn megferttkltík a 1.1 Ifpayppoi szerint rekorAnlns vírussal, és Mmutatjuk vagy meghatározzak, hogy a heterolög nyitott leolvasási keret által káífelí íemték e>ipfessx|löáik-e a sejtben, 22. M 140, igénypontok bármelyike szerinti vektor* vagy a :! !-2£k i0&yp®mk bármelyike -szériái vírus a terápiában történő alkalmazás céljára, 23. A 13,, IS* vagy 17, igénpom. szerinti virus paíogén ím&im vagy rák mellőzésében, gátlásában vagy kezelésében: történő alkalmazás céljára. 24. A?: 1-4,, 8. vagy 9. igpypínt szerinti vektor iinftuenza VÉiis öntözés megelőzésében vagy gátlásában töriénb alkalínaaás oéjjára, 25. A 11.. vagy 10. Igénypont szerinti Ars egy olyan betegség megelőzésében vagy kezelésében történő alkalmazásra, amelyet egy eniogérr fehérje ősökként mennyisége vagy hiánya jellemez.
- 26. Az 1-4, igénypontok bármelyike szerinti vektor alkalmazása olyan gyógyszer gyártásában, amellyel meg Met éléről a*. .ift&MÉ* vírus letűnt* vagy a II . igénypont szerinti vans alkalmazása olyan gyógyszer gyártásában, amelpf meg lehet előzni vagy kezeim lehet egy pategén fertőzést vagy rákot, vagy egy olyan betegséget, atnelpt égy endogén fehére csökkent mennyisége vagy hiánya jellemez.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35653802P | 2002-02-13 | 2002-02-13 | |
US43867903P | 2003-01-07 | 2003-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027448T2 true HUE027448T2 (hu) | 2016-09-28 |
Family
ID=34380774
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15197386A HUE050222T2 (hu) | 2002-02-13 | 2003-02-12 | Szignál influenzavírus-vektorok pakolására |
HUE03716017A HUE027448T2 (hu) | 2002-02-13 | 2003-02-12 | Szignál influenza vírusvektorok pakolására |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15197386A HUE050222T2 (hu) | 2002-02-13 | 2003-02-12 | Szignál influenzavírus-vektorok pakolására |
Country Status (13)
Country | Link |
---|---|
US (3) | US7226774B2 (hu) |
EP (2) | EP3009507B1 (hu) |
JP (1) | JP4430942B2 (hu) |
KR (1) | KR101113432B1 (hu) |
CN (1) | CN103540614B (hu) |
AU (2) | AU2003219745B8 (hu) |
BR (1) | BRPI0307679A2 (hu) |
CA (1) | CA2492097C (hu) |
ES (2) | ES2563402T3 (hu) |
HU (2) | HUE050222T2 (hu) |
IL (2) | IL163546A (hu) |
MX (1) | MXPA04007914A (hu) |
WO (1) | WO2003068923A2 (hu) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002068632A2 (en) | 2001-02-23 | 2002-09-06 | Wisconsin Alumni Research Foundation | Methods to identify mutant cells with altered sialic acid |
AU2003219745B8 (en) | 2002-02-13 | 2008-10-09 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
US8475806B2 (en) * | 2003-05-28 | 2013-07-02 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines and gene therapy |
EP1814990A2 (en) | 2004-11-19 | 2007-08-08 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with tandem transcription units |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
EP1917352A4 (en) * | 2005-06-21 | 2009-03-25 | Medimmune Vaccines Inc | METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE |
US7790434B2 (en) * | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
CN117587038A (zh) * | 2005-10-19 | 2024-02-23 | 佛罗里达大学研究基金公司 | 能够感染犬科动物的流感病毒及其用途 |
CA2647985C (en) * | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
JP5491173B2 (ja) | 2006-04-19 | 2014-05-14 | メディミューン,エルエルシー | イヌ細胞中でマイナス鎖ウイルスrnaを発現させるための方法および組成物 |
WO2007130330A2 (en) * | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
US8778353B2 (en) * | 2006-05-01 | 2014-07-15 | Technovax, Inc. | Influenza virus-like particle (VLP) compositions |
KR100702034B1 (ko) * | 2006-05-12 | 2007-03-30 | 삼성전자주식회사 | 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판 |
US8597661B2 (en) * | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
WO2008148104A1 (en) * | 2007-05-25 | 2008-12-04 | Novavax, Inc. | Novel vlps derived from cells that do not express a viral matrix or core protein |
US20110008837A1 (en) * | 2007-06-15 | 2011-01-13 | Marc-Andre D-Aoust | Modifying glycoprotein production in plans |
WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
NZ587108A (en) | 2007-11-27 | 2013-04-26 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
CA2730171C (en) * | 2008-07-08 | 2016-10-11 | Medicago Inc. | Soluble recombinant influenza antigens |
ES2593277T3 (es) * | 2008-07-18 | 2016-12-07 | Medicago Inc. | Nuevo epítopo de inmunización contra el virus de la influenza |
EP3009145A1 (en) | 2009-03-30 | 2016-04-20 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
MY182643A (en) | 2009-06-24 | 2021-01-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
JP5845180B2 (ja) * | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルス及びそれらの使用 |
ES2662778T3 (es) | 2009-09-22 | 2018-04-09 | Medicago Inc. | Método de preparación de proteínas derivadas de plantas |
JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
EP2576581A4 (en) * | 2010-06-06 | 2015-04-15 | Sinai School Medicine | RECOMBINANT RNA VIRUSES AND USES THEREOF |
TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型pb2遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
EP2758075B1 (en) | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
AU2013362935B2 (en) | 2012-12-18 | 2018-10-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
EP3341018A1 (en) | 2015-08-28 | 2018-07-04 | Wisconsin Alumni Research Foundation | Generation of infectious influenza viruses from virus-like particles |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
CA3023143A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
CN114908122B (zh) * | 2021-02-07 | 2024-05-07 | 广州恩宝生物医药科技有限公司 | 一种用于表达外源蛋白的新型流感病毒载体及其构建方法 |
CN113069540B (zh) * | 2021-03-15 | 2022-02-22 | 广州恩宝生物医药科技有限公司 | 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001634A (en) * | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
US5854037A (en) * | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5786199A (en) * | 1989-08-28 | 1998-07-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5658772A (en) | 1989-12-22 | 1997-08-19 | E. I. Du Pont De Nemours And Company | Site-specific recombination of DNA in plant cells |
US6843996B1 (en) * | 1995-06-05 | 2005-01-18 | Medimmune Vaccines, Inc. | Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation |
US6271011B1 (en) * | 1996-10-15 | 2001-08-07 | The University Of Georgia Research Foundation, Inc. | Pasteurella neuraminidase coding sequences and diagnostic methods |
ES2533622T3 (es) * | 1999-04-06 | 2015-04-13 | Wisconsin Alumni Research Foundation | Virus de la gripe recombinantes para vacunas y terapia génica |
EP1194580B2 (en) | 1999-07-14 | 2010-08-25 | Mount Sinai School of Medicine of New York University | In vitro reconstitution of segmented negative-strand rna viruses |
ATE488577T1 (de) * | 2000-04-14 | 2010-12-15 | Wisconsin Alumni Res Found | Mutiertes ionenkanalprotein enthaltende viren |
US20040241139A1 (en) * | 2000-07-20 | 2004-12-02 | Gerd Hobom | Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement |
EP1201760A1 (en) | 2000-10-30 | 2002-05-02 | ARTEMIS Pharmaceuticals GmbH | Influenza virus vector for human dendritic cells |
AU2003219745B8 (en) | 2002-02-13 | 2008-10-09 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
US20080292658A1 (en) | 2004-11-11 | 2008-11-27 | Emmie De Wit | Defective Influenza Virus Particles |
CA2647985C (en) * | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
US8597661B2 (en) * | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
-
2003
- 2003-02-12 AU AU2003219745A patent/AU2003219745B8/en not_active Expired
- 2003-02-12 EP EP15197386.4A patent/EP3009507B1/en not_active Expired - Lifetime
- 2003-02-12 CA CA2492097A patent/CA2492097C/en not_active Expired - Lifetime
- 2003-02-12 EP EP03716017.3A patent/EP1572910B1/en not_active Expired - Lifetime
- 2003-02-12 ES ES03716017.3T patent/ES2563402T3/es not_active Expired - Lifetime
- 2003-02-12 ES ES15197386T patent/ES2806412T3/es not_active Expired - Lifetime
- 2003-02-12 HU HUE15197386A patent/HUE050222T2/hu unknown
- 2003-02-12 KR KR1020107011520A patent/KR101113432B1/ko active IP Right Grant
- 2003-02-12 HU HUE03716017A patent/HUE027448T2/hu unknown
- 2003-02-12 US US10/366,630 patent/US7226774B2/en not_active Expired - Lifetime
- 2003-02-12 WO PCT/US2003/004233 patent/WO2003068923A2/en active Application Filing
- 2003-02-12 CN CN201310400039.8A patent/CN103540614B/zh not_active Expired - Lifetime
- 2003-02-12 JP JP2003568038A patent/JP4430942B2/ja not_active Expired - Lifetime
- 2003-02-12 BR BRPI0307679A patent/BRPI0307679A2/pt not_active Application Discontinuation
-
2004
- 2004-08-13 MX MXPA04007914A patent/MXPA04007914A/es active IP Right Grant
- 2004-08-15 IL IL163546A patent/IL163546A/en active IP Right Grant
-
2006
- 2006-08-24 US US11/509,249 patent/US7585657B2/en not_active Expired - Lifetime
-
2008
- 2008-07-17 AU AU2008203186A patent/AU2008203186B2/en not_active Expired
-
2009
- 2009-05-21 US US12/470,287 patent/US8298805B2/en not_active Expired - Lifetime
-
2011
- 2011-02-20 IL IL211324A patent/IL211324A0/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003219745B2 (en) | Signal for packaging of influenza virus vectors | |
US20210252130A1 (en) | Vaccines comprising mutant attenuated influenza viruses | |
US10119124B2 (en) | Influenza M2 protein mutant viruses as live influenza attenuated vaccines | |
US11180737B2 (en) | Generation of infectious influenza viruses from virus-like particles | |
CA2816242C (en) | Signal for packaging of influenza virus vectors | |
JP4456169B2 (ja) | インフルエンザウイルスベクターのパッケージングのためのシグナル |